Filing search / Intellia Therapeutics, Inc. / "Healthcare"

8-K

EX-99.1

NTLA Intellia Therapeutics, Inc.

27 Feb 25

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

7:45am

Barclays 27th Annual Global Healthcare Conference, March 11, Miami Jefferies Biotech on the Beach Summit, March 12, Miami Fourth Quarter and Full

8-K

EX-99.1

NTLA Intellia Therapeutics, Inc.

10 Jan 25

Intellia Therapeutics Announces Anticipated 2025 Milestones and Pipeline priorities result in NTLA-3001 discontinuation and select, research-focused investment

7:30am

for coverage and formulary decisions. Page 3 of 5 intelliatx.com Presentation at the 43rd Annual J.P. Morgan Healthcare Conference John Leonard, M.D … ., President and Chief Executive Officer of Intellia, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco

8-K

EX-99.1

NTLA Intellia Therapeutics, Inc.

25 Oct 24

Regulation FD Disclosure

4:59pm

and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug

8-K

EX-99.1

zmtw55xrgntshu0i2

8 Aug 24

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

7:45am

8-K

EX-99.1

5b3ya y8iq

14 Jun 24

Intellia Therapeutics Names Brian Goff to its Board of Directors

4:24pm

8-K

fy9mt6g5yk1

14 Jun 24

Intellia Therapeutics Names Brian Goff to its Board of Directors

4:24pm

8-K

EX-99.1

x3ysip

9 May 24

Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

7:40am

8-K

EX-99.1

jcemr9bxk2s30

15 Apr 24

Departure of Directors or Certain Officers

4:21pm

424B5

e5vw0

26 Feb 24

Prospectus supplement for primary offering

7:04am

424B5

kzrf9ve5

23 Feb 24

Prospectus supplement for primary offering

5:22pm

8-K

EX-99.1

osh34 eqguozak

22 Feb 24

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

7:45am

8-K

EX-99.1

7s9knbilm5

1 Feb 24

Regulation FD Disclosure

4:05pm

8-K

EX-99.1

vyosle nsl

4 Jan 24

Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones

4:07pm